The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The full article is available to subscribers Subscriber Login   
Revised 2/6/18: Footnote 15 was added to Table 2 and the Dosage and Administration section was revised to reflect the availability of separate pens for 0.5-mg and 1.0-mg doses of Ozempic. The SUSTAIN-7 trial was added to Table 3 and the Clinical Studies section.

The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.

GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent secretion of insulin, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with average weight loss of 1.5-2.8 kg, and rarely cause hypoglycemia.1

Cardiovascular Effects – In patients with type 2 diabetes and high cardiovascular risk, addition of liraglutide (Victoza) to standard therapy has been shown to reduce the rates of major ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
Article code: 1539b
 Electronic, downloadable article - $25